{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:05Z","timestamp":1791855785023,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170705"],"award-info":[{"award-number":["82170705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322012"],"award-info":[{"award-number":["82322012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ekir.2026.106497","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:09:15Z","timestamp":1774368555000},"page":"106497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome"],"prefix":"10.1016","volume":"11","author":[{"given":"Yifan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106497_bib1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"Orth","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106497_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/EDE.0000000000001576","article-title":"Twenty-four-year trends in incidence and mortality of nephrotic syndrome: a population-based cohort study","volume":"34","author":"Vestergaard","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.ekir.2026.106497_bib3","first-page":"479","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner","year":"2016","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ekir.2026.106497_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106497_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00011-013-0672-6","article-title":"The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies","volume":"63","author":"Pereira Wde","year":"2014","journal-title":"Inflamm Res"},{"key":"10.1016\/j.ekir.2026.106497_bib6","article-title":"Corticosteroid therapy for nephrotic syndrome in children","volume":"8","author":"Hahn","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ekir.2026.106497_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2026.106497_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000546655","article-title":"Clinical outcomes in the nephrotic syndrome study network: disease burden and treatment patterns over time","volume":"5","author":"Drexler","year":"2025","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.ekir.2026.106497_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and regulatory B cells in immune-mediated kidney disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823204","article-title":"B-cell dysregulation in idiopathic nephrotic syndrome: what we know and what we need to discover","volume":"13","author":"Colucci","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106497_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1363102","article-title":"Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells","volume":"15","author":"Dabkowska","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106497_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1001\/jama.2025.19316","article-title":"Rituximab for relapsing nephrotic syndrome in adults: a randomized clinical trial","volume":"334","author":"Isaka","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.106497_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40259-017-0221-x","article-title":"Rituximab for steroid-dependent or frequently relapsing idiopathic nephrotic syndrome in adults: a retrospective, multicenter study in Spain","volume":"31","author":"DaSilva","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ekir.2026.106497_bib15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2215\/CJN.08570722","article-title":"Use of rituximab in childhood idiopathic nephrotic syndrome","volume":"18","author":"Chan","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study","volume":"33","author":"Chan","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","article-title":"Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children","volume":"24","author":"Kamei","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","article-title":"Obinutuzumab: what is there to learn from clinical trials?","volume":"130","author":"Cartron","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106497_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106497_bib20","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106497_bib22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106497_bib23","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/ndt\/gfaf021","article-title":"Obinutuzumab for the management of immune-mediated glomerular diseases","volume":"40","author":"Rossi","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106497_bib24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106497_bib25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib26","first-page":"111","article-title":"Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab","volume":"56","author":"Lin","year":"2025","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib27","article-title":"Case report: effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106497_bib28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ndt\/gfae061","article-title":"Obinutuzumab is effective for the treatment of frequently-relapsing\/steroid-dependent minimal change disease in adults","volume":"39","author":"Jin","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106497_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf039","article-title":"The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2026.106497_bib30","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106497_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2215\/CJN.0000000898","article-title":"Treatment response rates and kidney outcomes among adults with primary focal segmental glomerulosclerosis","volume":"21","author":"Sim","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1053\/j.ajkd.2022.11.012","article-title":"Age of onset and disease course in biopsy-proven minimal change disease: an analysis from the Cure Glomerulopathy Network","volume":"81","author":"Chen","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106497_bib33","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ndt\/gfac238","article-title":"Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis","volume":"38","author":"Jauhal","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"80","key":"10.1016\/j.ekir.2026.106497_bib34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2026.106497_bib35","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.kint.2018.04.024","article-title":"Acute kidney injury complicating nephrotic syndrome of minimal change disease","volume":"94","author":"Meyrier","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106497_bib36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2215\/CJN.17331120","article-title":"Nephrologist Follow-Up versus Usual Care after an Acute Kidney Injury Hospitalization (Fusion): a randomized controlled trial","volume":"16","author":"Silver","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106497_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109211","article-title":"Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: a two-center prospective cohort study","volume":"246","author":"Xu","year":"2023","journal-title":"Clin Immunol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:24:22Z","timestamp":1780478662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468024926027294"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106497","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103728","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106497"}}